Content continues after advertisement

Therapeutics Research Note: Pasireotide & Hypersomatotropism

Clinician's Brief (Capsule)

Sign in to Print/View PDF

Hypersomatotropism is an underlying cause of insulin-resistant diabetes mellitus in cats. Pasireotide, a somatostatin analog, improves hypersomatotropism control in humans. 

In this 5-day study, 12 cats were treated with short-acting pasireotide twice a day on days 2 through 4. All had significantly lower serum insulin-like growth factor-1, a biomarker for hypersomatotropism, on day 5 as compared with baseline. Blood glucose curves on days 1 and 5 were unchanged; however, the required insulin dose was lower. Three cats experienced diarrhea; 5 had subclinical hypoglycemia that resolved with feeding. The authors conclude that pasireotide effectively manages hypersomatotropism in cats and causes increased insulin sensitivity.

This capsule is part of the One Health Initiative.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy